Enanta Pharmaceuticals Inc $ 70.7 0 (0%)
| Volume: | 155,558 | Avg Vol (1m): | 190,236 |
| Market Cap $: | 1.39 Bil | Enterprise Value $: | 1.00 Bil |
| P/E (TTM): | 22.92 | P/B: | 3.37 |
Manual of Stocks™ Web
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1737.71 | ||
| Equity-to-Asset | 0.95 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 35.05 | ||
| Beneish M-Score | -3.31 | ||
| WACC vs ROIC | |||
Profitability | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 29.29 | ||
| Net Margin % | 29.22 | ||
| ROE % | 15.64 | ||
| ROA % | 14.8 | ||
| ROC (Joel Greenblatt) % | 112.83 | ||
| 3-Year Revenue Growth Rate | 8.7 | ||
| 3-Year EBITDA Growth Rate | -10.4 | ||
| 3-Year EPS without NRI Growth Rate | -5.2 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 22.92 | ||
| PE Ratio without NRI | 22.92 | ||
| Price-to-Owner-Earnings | 20.24 | ||
| PB Ratio | 3.37 | ||
| PS Ratio | 6.67 | ||
| Price-to-Free-Cash-Flow | 17.33 | ||
| Price-to-Operating-Cash-Flow | 16.27 | ||
| EV-to-EBIT | 15.55 | ||
| EV-to-EBITDA | 14.8 | ||
| EV-to-Revenue | 4.51 | ||
| PEG Ratio | 1.04 | ||
| Current Ratio | 22.01 | ||
| Quick Ratio | 22.01 | ||
| Days Sales Outstanding | 73.25 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.33 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 1.5 | ||
| Price-to-Median-PS-Value | 0.84 | ||
| Price-to-Graham-Number | 1.84 | ||
| Earnings Yield (Greenblatt) % | 6.37 |